In a double-blind trial alprenolol IOO mg four times daily or placebo was given to 87 patientsfor one year from onset of their acute myocardial infarction. Patients were assessed on five occasions after their discharge from hospital. The mortality and hospital readmission rates were not significantly different in the two groups. This also applied to the incidence of cardiac failure, exertional dyspnoea, andfrequency of ventricular ectopic beats. The incidence of angina pectoris and the consumption of trinitrin were also not significantly different. The patients taking alprenolol had a significantly better rehabilitation rate judged by return to work. No injurious effect of alprenolol on the myocardium was observed using heart volume measurements as a criterion. There was a significant fall in resting systolic blood pressure between three months and one year in the patients on alprenolol and the systolic blood pressure during exercise on alprenolol was also significantly lower. Most patients felt better when exercised while taking alprenolol but there was no significant difference in the frequency of angina or ischaemic changes in the electrocardiogram during exercise with or without alprenolol. Ventilation and 02 uptake at rest and during exercise were lower on alprenolol. No bronchoconstrictor effect from alprenolol was detected.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.